Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
The uncertainty over the biotech's lead clinical asset weighed on its shares last month.
Investors are running for the hills following the company's latest clinical update.
No podcast episodes available.
ADVM earnings call for the period ending December 31, 2020.
ADVM earnings call for the period ending June 30, 2020.
ADVM earnings call for the period ending March 31, 2020.
ADVM earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.